SecBot SecBot
DEFA14A ·Filed Apr 16, 2026

VIR

Vir Biotechnology, Inc.
NEUTRAL
Impact 3/10
Horizonimmediate Processed7mo ago SEC0001628280-26-025380
Proxy solicitation materials
Actionable Insight • Neutral

This is a routine filing with no immediate trading implications. Monitor for any future filings that might indicate a more significant corporate action.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$10.33
T+0 close · Apr 16, 2026 · via day close
Latest settled
−5.91%
T+60 · $9.72
Vs SPY
−12.95%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Apr 16 $10.33entry
  2. T+1 · 7mo ago +4.07%α +2.85% · $10.75
  3. T+5 · 7mo ago +0.19%α −0.79% · $10.35
  4. T+20 · 6mo ago −9.68%α −15.50% · $9.33
  5. T+60 · 4mo ago −5.91%α −12.95% · $9.72
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Vir Biotechnology filed a definitive proxy statement (DEFA14A) following the recent departure of its Chief Medical Officer, Mark Eisner. The filing is routine and does not indicate any material changes or shareholder disputes.

Key Financial Metrics

Vote
director election

Key Facts

  • Filed a DEFA14A proxy statement
  • Follows the recent departure of Chief Medical Officer Mark Eisner
  • No activist campaign or shareholder dispute mentioned
  • Filing is routine and procedural

Financial Impact

No material financial impact

Risk Factors

  • Potential for future management changes

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Investment Themes

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
DEFA14A Filing (Primary)0001628280-26-025380
Document: 0001628280-26-025380-index-headers.html0001628280-26-025380
Document: 0001628280-26-025380-index.html0001628280-26-025380
Document: 0001628280-26-025380.txt0001628280-26-025380

Track record

36 reports on VIR

Performance horizon

4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +29.79% at T+5 after the Nov 6, 2026 report. 5 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today 424B5 Bearish 5/10 Entry price pending
  2. Nov 13, 20263d ago 8-K Bearish 5/10 Entry $9.92 Now $9.58 +3.43% settles Nov 23
  3. Nov 12, 20264d ago 424B5 Bearish 5/10 Entry $9.96 Now $9.58 +3.82% settles Nov 20
  4. Nov 12, 20264d ago S-3ASR Neutral 3/10 Entry $9.96 Now $9.58 −3.82% settles Nov 20
  5. Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $13.15 Now $9.58 −27.15% settles Nov 17
  6. Nov 9, 20267d ago 8-K Bullish 6/10 Entry $13.65 to $9.58 Now $9.58 −29.79% ▼ −29.79% −28.10% vs SPY
  7. Nov 6, 202610d ago SC 13D/A Bearish 5/10 Entry $13.65 to $9.58 Now $9.58 +29.79% ▲ +29.79% +28.10% vs SPY
  8. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $11.02 to $12.12 Now $9.58 −13.07% ▲ +9.98% +6.69% vs SPY
  9. Nov 3, 202613d ago 144 Neutral 2/10 Entry $11.22 to $13.15 Now $9.58 −14.62% ▲ +17.20% +17.79% vs SPY
  10. Nov 2, 202614d ago 144 Neutral 1/10 Entry $11.00 to $13.65 Now $9.58 −12.91% ▲ +24.05% +23.97% vs SPY
Showing 10 of 36

US Market Status

Market Closed · Opens Wed (9h 33m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Apr 16, 2026